Trial Profile
Extension Study for Patients Who Completed GENA-05 (NuProtect)- to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Aug 2023
Price :
$35
*
At a glance
- Drugs Simoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Pharmacodynamics; Registrational
- Acronyms NuProtect-Extension study
- Sponsors Octapharma
- 01 Jul 2023 Results reporting data on long-term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A published in the Haemophilia
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 13 Jul 2020 According to an Octapharma media release, results from this study will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, 2020.